首页 | 本学科首页   官方微博 | 高级检索  
检索        

紫龙金片联合含铂类化疗方案治疗非小细胞肺癌Meta分析
引用本文:蔡秋晗,张婵婵,仇雅朋,贺云杰,吕萌,侯建松,郭秋香.紫龙金片联合含铂类化疗方案治疗非小细胞肺癌Meta分析[J].世界中医药,2021(4):618-625,632.
作者姓名:蔡秋晗  张婵婵  仇雅朋  贺云杰  吕萌  侯建松  郭秋香
作者单位:1 天津中医药大学第一附属医院临床试验中心,天津,300193; 2 天津中新药业集团股份有限公司隆顺榕制药厂,天津,300193; 3 北京市天之力医药科技开发有限公司临床部,北京,100020
基金项目:天津市科技计划项目(14ZCDZSY00027)
摘    要:目的:系统评价紫龙金片联合含铂类化疗方案治疗非小细胞肺癌患者的有效性及安全性。方法:检索中国生物医学文献数据库(CBM),国家知识基础设施数据库(简称中国知网,China National Knowledge Infrastructure,CNKI),中文科技期刊数据库(简称维普资讯,Chinese Citation Database,CCD),中国学术期刊数据库(简称万方数据库,China Science Periodical Database,CSPD),PubMed,EMbase,CochraneLibrary,检索时限均从建库至2018年12月。按照纳排标准筛选文献,对纳入文献进行信息提取,使用Revman进行统计分析。结果:共纳入12项研究。与对照组比较,紫龙金片联合含铂类化疗方案可提高实体瘤稳定率(OR=1.91,95%CI为1.02~3.58,P=0.04),优化患者生命质量(OR=8.21,95%CI为3.24~20.78,P<0.00001),改善中医证候(OR=246.16,95%CI为70.10~864.39,P<0.00001),增强NK细胞活性(MD=8.38,95%CI为6.56~10.19,P<0.00001),提高T淋巴细胞亚群水平;与对照组比较,观察组消化系统(OR=0.43,95%CI为0.29~0.65,P<0.0001)、血液系统(OR=0.38,95%CI为0.27~0.54,P<0.0001)、肝肾功能损伤(OR=0.40,95%CI为0.19~0.87,P=0.02)的不良反应发生率较低,且差异均有统计学意义。结论:紫龙金片联合含铂类化疗方案治疗非小细胞肺癌患者具有较好的辅助治疗作用,可提高患者生命质量,改善免疫功能,临床治疗安全性较好。

关 键 词:紫龙金片  铂类化疗方案  非小细胞肺癌  随机对照试验  META分析  系统评价  疗效  安全性
收稿时间:2019/5/17 0:00:00

Zilongjin Tablet Combined with Platinum Chemotherapy in Non-Small Cell Lung Cancer:a Meta-Analysis
CAI Qiuhan,ZHANG Chanchan,QIU Yapeng,HE Yunjie,LYU Meng,HOU Jiansong,GUO Qiuxiang.Zilongjin Tablet Combined with Platinum Chemotherapy in Non-Small Cell Lung Cancer:a Meta-Analysis[J].World Chinese Medicine,2021(4):618-625,632.
Authors:CAI Qiuhan  ZHANG Chanchan  QIU Yapeng  HE Yunjie  LYU Meng  HOU Jiansong  GUO Qiuxiang
Institution:1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China; 2 Longshunrong Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group co.LTD,Tianjin 300193,China; 3 Beijing Tianzhili Pharmaceutical Technology Development co.LTD,Beijing 100020,China
Abstract:Objective:To systematically review the efficacy and safety of Zilongjin Tablet combined with platinum chemotherapy in NSCLC.Methods:Literature was retrieved in CNKI,Wanfang Data,VIP,CBM,Pubmed,Embase and Cochrane library.The search time was up to December 2018.Literature was screened according to inclusion criteria,and available information included was extracted.Meta-analysis was performed by Revman 5.3.Results:A total of 12 studies were included.Compared with the control group,Zilongjin Tablets combined with platinum-containing chemotherapy can increase the stable rate of solid tumorsOR=1.91,95%CI(1.02~3.58),P=0.04],improve the quality of lifeOR=8.21,95%CI(3.24~20.78),P<0.00001],relieve TCM syndromeOR=246.16,95%CI(70.10~864.39),P<0.00001],promote activity of NK cellsMD=8.38,95%CI(6.56~10.19)P<0.00001]and improve T lymphocyte subpopulation level.Compared with the control group,digestive system in the test groupOR=0.43,95%CI(0.29~0.65),P<0.0001],blood systemOR=0.38,95%CI(0.27~0.54,P<0.0001]and hepatic and renal functionOR=0.40,95%CI(0.19~0.87),P=0.02].The incidence of adverse reactions of those was low and all are statistically significant.Conclusion:Zilongjin Tablet has better efficacy and safety when used as adjuvant therapy combine with platinum chemotherapy on treating non-small cell lung cancer.It can improve the quality of life of patients,improve the immune function,and have better clinical treatment safety.
Keywords:Zilongjin Tablet  Platinum chemotherapy  NSCLC  Randomized controlled trial  Meta-analysis  Systematic review  Efficacy  Safety
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《世界中医药》浏览原始摘要信息
点击此处可从《世界中医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号